Nasus Pharma (NSRX) 13G: Udi Gilboa reports 21.1% stake
Nasus Pharma Ltd. (NSRX): Udi Gilboa filed a Schedule 13G reporting beneficial ownership of 1,901,311 ordinary shares, representing 21.1% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nasus Pharma Ltd. (NSRX): Udi Gilboa filed a Schedule 13G reporting beneficial ownership of 1,901,311 ordinary shares, representing 21.1% of the class. He holds sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive power.
The percentage is based on 9,014,105 ordinary shares outstanding as of September 30, 2025, as advised to the reporting person. The filing relates to Ordinary Shares (CUSIP M7071P109), and identifies Gilboa as a citizen of Israel.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in NSRX did Udi Gilboa report in the Schedule 13G?
What class of NSRX securities is covered and what is the CUSIP?
What is the citizenship of the reporting person in the NSRX 13G?
Is the reported NSRX ownership held jointly with others?
AI-generated analysis. How Rhea-AI works. Not financial advice.